Aqupla (nedaplatin)

After multiple-line treatment including chemotherapy, targeted therapy, and immunotherapy, disease control was achieved in a case of advanced pulmonary adenocarcinoma carrying the KRAS G12C mutation by mutation-specific inhibitor therapy, and the adverse reactions to the therapy were tolerable.

P=N/A, N=30, Not yet recruiting, Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital

The patient started first-line therapy with osimertinib combined with pemetrexed/nedaplatin, resulting in a transient partial response, significant resolution of pleural effusion, and partial regression of the primary tumor. The patient achieved only transient disease control following treatment with a third-generation EGFR TKI combined with chemoradiotherapy. Further research to explore optimal therapeutic strategies for such complex molecular profiles is needed.

P2, N=118, Completed, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Enrolling by invitation --> Completed | N=62 --> 118 | Trial completion date: Dec 2024 --> Aug 2025 | Trial primary completion date: Apr 2024 --> Aug 2025

P1/2, N=86, Recruiting, Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Not yet recruiting --> Recruiting

P4, N=50, Not yet recruiting, Gansu Provincial Hospital; Gansu Provincial People's Hospital

Patients were divided into two groups: an experimental group (n = 41) treated with a combination of platinum-based chemotherapy (pemetrexed and nedaplatin) and the PD-1 inhibitor cindilizumab, and a control group (n = 41) treated with conventional platinum-based chemotherapy. These findings support the integration of neoadjuvant immunotherapy and chemotherapy as a promising strategy for treating stage IIIa NSCLC, offering improved resection rates, survival, and reduced complications. Further research is warranted to optimize treatment protocols and validate these results in larger, multicentre studies.

Between 2013 and 2021, she underwent palliative chemotherapy comprising paclitaxel liposomes, cisplatin/nedaplatin, S-1/raltitrexed, irinotecan, doxorubicin, vinorebine, toripalimab, apatinib, gemcitabine, oxaliplatin, and capecitabine, as well as two debulking surgeries. From November 2021, she received six cycles of tislelizumab (a PD-1 inhibitor), paclitaxel (albumin-bound), and carboplatin, to which a partial response was observed according to the Response Evaluation Criteria in Solid Tumors. From May 2022, the patient was switched to maintenance therapy with tislelizumab plus olaparib...We report a case involving a patient with highly pretreated recurrent ovarian cancer who exhibited prolonged PFS after developing three irAEs. The distinctly prolonged PFS observed, along with the reviewed literature, suggests that irAEs may be correlated with improved survival in ovarian cancer.

This case underscores the potential efficacy of combining immune checkpoint inhibitors with small-molecule multi-targeted tyrosine kinase inhibitors in treating advanced SCC of the lung after progression on first-line therapy. The complementary mechanisms of immune modulation and tumor microenvironment normalization may offer an effective strategy for addressing immune resistance in SCC.

P2, N=26, Not yet recruiting, The First Affiliated Hospital of Xiamen University

The combination of nedaplatin with paclitaxel liposomes or docetaxel demonstrated comparable efficacy in ROC patients, effectively reducing tumor and inflammatory markers without increasing adverse reactions. Importantly, the combination of nedaplatin and docetaxel significantly improved PFS.

P1/2, N=86, Not yet recruiting, Wigen Biomedicine Technology (Shanghai) Co., Ltd.